Compare United States Copper Index Fund (CPER) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs BIO-TECHNE Corp — how do they compare? United States Copper Index Fund trades at $38.57, while BIO-TECHNE Corp trades at $71.48 (market cap $11.10B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while United States Copper Index Fund pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, United States Copper Index Fund nearer its low. Which is the better fit depends on your goals.
| CPER | TECH | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $40.60 | $71.38 |
52-Week Low | $27.21 | $43.31 |
Market Cap | — | $11.10B |
Enterprise Value | — | $11.18B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER, the United States Copper Index Fund, trades at $37.94, down 0.13% on the day, with a bullish technical signal driven by moving averages. Recent news highlights copper's strong performance tied to AI and electrification demand, with articles from 24/7 Wall Street and Reuters in July 2026 noting copper's 33% annual gain and structural demand drivers. Key support and resistance cluster around $38.
The outlook for CPER remains positive given copper's fundamental role in energy transition and AI infrastructure, though risks include potential global manufacturing weakness and substitution threats from aluminum. Investor sentiment is buoyant, but price sensitivity to macroeconomic trends warrants caution.
Bio-Techne (TECH) trades at $71.36, showing minimal daily movement (+0.08%) as the market digests Merck KGaA's $73 per share acquisition offer. The stock sits just 2.3% below the buyout price, with technical indicators showing bullish momentum. Fundamentally, the company maintains strong gross margins (64.96%) but faces declining net income margins (6.01% in 2025). Recent earnings show mixed results with one beat and two misses in the last four quarters.
The acquisition premium provides near-term upside potential, though shareholder litigation risks exist regarding deal fairness. Long-term investors face uncertainty about post-acquisition prospects, while current valuation metrics (P/E 101.94) appear stretched without the takeover scenario. The $73 offer price represents the primary catalyst, with downside risk to $50 if the deal fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
